Ask AI
Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies
Interactive Case Challenges: Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies

Released: April 30, 2025

Activity

Progress
1
Course Completed

Case History and Presentation 
After 16 weeks of lebrikizumab therapy, Anna reports significant improvement in her symptoms: 

  • EASI score: reduced to 12
  • Itch Numeric Rating Scale: 3/10 
  • Improved sleep and quality of life 

However, Anna experiences mild flares triggered by cold weather or high-stress situations, particularly at work. These episodes, although less severe than before, still affect her confidence and routine. 

What additional recommendations would you provide to optimize Anna’s care?